Ancestim

Ancestim

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation
ATC code	L03AA12 (WHO)
Pharmacokinetic data
Elimination half-life	2.5 h
Excretion	renal: 90%
Identifiers
CAS Number	163545-26-4 N
ChemSpider	none
UNII	PYB4Q6JG41
KEGG	D02937 Y
NY (what is this?)  (verify)

Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.^[1]

It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.^[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation in certain cancer patients.^[3]

References

0.00 (0 votes)